Matteo Simone holds a PhD in Pharmaceutical Sciences from the University of Genoa. He gained experience in breast cancer stem cells at the European Institute of Oncology and explored benzimidazolic derivatives as cytotoxic and antiviral agents at the Mario Negri Institute, contributing to developing the marketed drug Trabectedin. He has over 15 years of experience in microbial products from actinomycetes, contributing to the identification and characterization of novel metabolites and the development of automated processes for metabolite annotation. He has co-authored over 20 publications and patent applications in the field of natural products. Currently, he is mainly involved in developing next version of the micro4all Platform.
Co-founder and Scientist
